CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that DefenCath has received an Innovative Technology designation from Vizient®, the largest healthcare performance improvement company in the country. CorMedix exhibited DefenCath at the Vizient Innovative Technology Exchange September 17^th in Las Vegas, Nevada.